# A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

> **NCT06181435** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 589 (actual)

## Conditions studied

- Dermatitis Atopic

## Interventions

- **DRUG:** Amlitelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06181435
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-21
- **Primary completion:** 2025-11-25
- **Final completion:** 2026-03-12
- **Target enrollment:** 589 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06181435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06181435, "A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06181435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*